Global Preventive Vaccines Market Growth, Share, Size, Trends and Forecast (2024 - 2030)
By Vaccine Type;
Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vector Vaccines, DNA Vaccines, and Others.By Disease Indication;
Pneumococcal Vaccines, Poliovirus, Hepatitis, Influenza, Measles, Mumps, Rubella (MMR), Varicella, Human Papilloma Virus, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2020 - 2030).Introduction
Global Preventive Vaccines Market (USD Million), 2020 - 2030
In the year 2023, the Global Preventive Vaccines Market was valued at USD 64,281.64 million. The size of this market is expected to increase to USD 135,662.67 million by the year 2030, while growing at a Compounded Annual Growth Rate (CAGR) of 11.3%.
The Global Preventive Vaccines Market is a dynamic and rapidly evolving sector within the broader pharmaceutical industry, primarily focused on the development and distribution of vaccines designed to prevent infectious diseases. This market is driven by the increasing awareness of the importance of immunization in maintaining public health, reducing healthcare costs, and preventing the spread of contagious diseases. Vaccines are biological preparations that provide immunity against specific pathogens, and their development involves rigorous research, extensive clinical trials, and stringent regulatory approvals to ensure their safety and efficacy.
In recent years, the preventive vaccines market has witnessed significant growth, propelled by advancements in biotechnology, increased investment in research and development, and the urgent need to combat emerging infectious diseases, such as COVID-19. The pandemic underscored the critical role vaccines play in controlling outbreaks, leading to unprecedented global collaboration and rapid innovation in vaccine technology, including mRNA vaccines. This has not only accelerated the development timelines but also broadened the scope of vaccine platforms and delivery methods, making vaccines more accessible and effective.
The market is characterized by a diverse range of stakeholders, including pharmaceutical companies, biotech firms, government agencies, and non-governmental organizations, all working collaboratively to enhance vaccine coverage and equity. Additionally, initiatives such as the Global Vaccine Action Plan and the COVAX facility aim to ensure that vaccines reach populations in low- and middle-income countries, addressing disparities in healthcare access. As the market continues to expand, it faces challenges such as vaccine hesitancy, supply chain logistics, and the need for continuous monitoring of vaccine safety and effectiveness. However, the ongoing innovations and concerted global efforts present a promising future for the preventive vaccines market, with the potential to significantly improve global health outcomes.
Global Preventive Vaccines Market Recent Developments & Report Snapshot
Recent Developments:
-
In August 2022, AstraZeneca's Evusheld (tixagevimab and cilgavimab, previously known as AZD7442) received approval in Japan for both the prevention (pre-exposure prophylaxis) and treatment of symptomatic disease resulting from SARS-CoV-2 infection.
-
In June 2022, the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) approved VBI Vaccines' PreHevbri (recombinant, adsorbed hepatitis B vaccine) for active immunization against infections caused by all known subtypes of the hepatitis B virus (HBV) in adults.
Parameters | Description |
---|---|
Market | Global Preventive Vaccines Market |
Study Period | 2020 - 2030 |
Base Year (for Preventive Vaccines Market Size Estimates) | 2023 |
Drivers |
|
Restraints |
|
Opportunities |
|
Segment Analysis
This report extensively covers different segments of Global Preventive Vaccines Market and provides an in depth analysis (including revenue analysis for both historic and forecast periods) for all the market segments.
The Global Preventive Vaccines Market is categorized by various types of vaccines, each employing different technologies to elicit immune responses and provide protection against infectious diseases. Live/attenuated vaccines use weakened forms of the pathogen to stimulate immunity without causing the disease. Inactivated vaccines contain killed pathogens, making them safer for people with weakened immune systems. Subunit vaccines include only parts of the pathogen, such as proteins, to trigger an immune response. Toxoid vaccines use inactivated toxins produced by the pathogen to build immunity against the toxins rather than the pathogen itself. Conjugate vaccines link antigens to a carrier protein to improve immunogenicity in young children. Recombinant vector vaccines use a virus or bacterium to deliver pathogen genes, while DNA vaccines involve injecting genetic material to produce antigens and stimulate immunity. Other innovative approaches are continually emerging, broadening the range of preventive strategies available.
The market segmentation also includes a focus on specific disease indications. Pneumococcal vaccines protect against infections caused by Streptococcus pneumoniae, a major cause of pneumonia, meningitis, and sepsis. Poliovirus vaccines aim to eradicate polio, a debilitating viral disease. Hepatitis vaccines prevent hepatitis A and B infections, reducing the risk of liver diseases. Influenza vaccines are critical for controlling seasonal flu outbreaks. The MMR vaccine protects against measles, mumps, and rubella, while the varicella vaccine prevents chickenpox. Human papillomavirus (HPV) vaccines reduce the risk of cervical and other cancers. Other vaccines address various infectious diseases, demonstrating the market’s comprehensive approach to disease prevention.
Geographically, the preventive vaccines market spans across North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America. North America leads in vaccine research, development, and uptake due to substantial investments in healthcare infrastructure and R&D. Europe follows closely, benefiting from robust healthcare systems and collaborative public health initiatives. The Asia Pacific region is experiencing rapid market growth, driven by large population bases, increasing healthcare access, and rising awareness of vaccination benefits. The Middle East and Africa and Latin America are also showing progress, with efforts to improve vaccine coverage and address public health challenges. Each region presents unique opportunities and challenges, influencing the global distribution and implementation of preventive vaccination programs.
Global Preventive Vaccines Segment Analysis
In this report, the Global Preventive Vaccines Market has been segmented by Vaccine Type, Disease Indication and Geography.
Global Preventive Vaccines Market, Segmentation by Vaccine Type
The Global Preventive Vaccines Market has been segmented by Vaccine Type into Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, Conjugate Vaccines, Recombinant Vector Vaccines, DNA Vaccines and Others.
These vaccines, such as the measles, mumps, and rubella (MMR) vaccine, elicit strong and long-lasting immune responses. Inactivated vaccines, on the other hand, contain pathogens that have been killed or inactivated so they cannot cause disease. Examples include the polio and hepatitis A vaccines. These vaccines are generally safer for individuals with compromised immune systems, although they often require multiple doses to achieve and maintain immunity.
Subunit, recombinant, and conjugate vaccines represent another category, using only parts of the pathogen (such as proteins or sugars) to provoke an immune response. Subunit vaccines, like the hepatitis B vaccine, and conjugate vaccines, such as the Haemophilus influenzae type b (Hib) vaccine, are designed to target specific components of the pathogen, reducing the risk of adverse reactions while still providing effective immunity. Recombinant vaccines, which utilize genetically engineered antigens, include the human papillomavirus (HPV) vaccine. These vaccines offer advantages in terms of safety and the ability to produce large quantities through biotechnological processes.
Further innovations in the vaccine market include toxoid, recombinant vector, and DNA vaccines. Toxoid vaccines, like the diphtheria and tetanus vaccines, use inactivated toxins produced by bacteria to build immunity against the harmful effects of these toxins. Recombinant vector vaccines employ a virus or bacterium to deliver pathogen genes, prompting the body to produce antigens and generate an immune response. The Ebola vaccine is an example of this technology. DNA vaccines represent a cutting-edge approach, involving the direct injection of genetic material (DNA) to produce antigens in the body, initiating an immune response. While still largely experimental, DNA vaccines hold promise for their ability to be rapidly developed and manufactured, exemplified by ongoing research for vaccines against various diseases including Zika virus and certain cancers. The continuous evolution and diversification of vaccine types reflect the market's commitment to addressing a wide array of infectious diseases with tailored immunization strategies.
Global Preventive Vaccines Market, Segmentation by Disease Indication
The Global Preventive Vaccines Market has been segmented by Disease Indication into Pneumococcal Vaccines, Poliovirus, Hepatitis, Influenza, Measles, Mumps, Rubella (MMR), Varicella, Human Papilloma Virus and Others.
Pneumococcal vaccines protect against infections caused by Streptococcus pneumoniae, which can lead to pneumonia, meningitis, and bloodstream infections. These vaccines, such as Prevnar 13 and Pneumovax 23, are particularly vital for young children, the elderly, and individuals with weakened immune systems. Poliovirus vaccines, including the inactivated polio vaccine (IPV) and oral polio vaccine (OPV), aim to eradicate polio, a highly contagious viral disease that can cause paralysis and even death. Hepatitis vaccines target hepatitis A and B viruses, preventing liver infections that can lead to severe liver disease and cancer, with vaccines like Havrix and Engerix-B being widely administered.
Influenza vaccines are essential for controlling seasonal flu outbreaks, which can cause severe illness and death, especially in vulnerable populations such as the elderly, young children, and those with chronic health conditions. These vaccines, updated annually to match circulating strains, include Fluzone and Fluarix. The MMR vaccine protects against measles, mumps, and rubella, all of which can cause serious health complications. Varicella vaccines, like Varivax, prevent chickenpox, a common and highly contagious childhood disease that can lead to severe complications in adults and immunocompromised individuals. Human papillomavirus (HPV) vaccines, such as Gardasil and Cervarix, are crucial in reducing the risk of cervical, anal, and other cancers caused by HPV infections.
The market also includes vaccines for a variety of other diseases. For instance, the Bacillus Calmette-Guérin (BCG) vaccine is used to prevent tuberculosis, especially in countries with high incidence rates. Rotavirus vaccines, like RotaTeq and Rotarix, protect against a common cause of severe diarrhea in infants and young children. Vaccines for emerging diseases, such as the Ebola and COVID-19 vaccines, highlight the market's responsiveness to new public health threats. Additionally, vaccines against dengue, typhoid, and cholera address significant global health challenges, particularly in low- and middle-income countries. The diverse range of disease indications in the preventive vaccines market underscores the ongoing efforts to combat both long-standing and emerging infectious diseases through effective immunization strategies.
Global Preventive Vaccines Market, Segmentation by Geography
In this report, the Global Preventive Vaccines Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Preventive Vaccines Market Share (%), by Geographical Region, 2023
North America, comprising the United States and Canada primarily, holds a significant share in the market owing to its advanced healthcare infrastructure, high healthcare expenditure, and robust vaccination programs. The region is characterized by extensive research and development activities, leading to the development of innovative vaccines and widespread immunization campaigns against diseases such as influenza, HPV, and COVID-19.
Europe, including countries like Germany, France, and the United Kingdom, is another key market for preventive vaccines. The region boasts stringent regulatory standards, well-established healthcare systems, and proactive public health policies, resulting in high vaccination rates and low incidence of vaccine-preventable diseases. European vaccine manufacturers play a crucial role in supplying vaccines globally and collaborating with international organizations to address public health challenges.
The Asia Pacific region, encompassing countries such as China, India, and Japan, represents a rapidly growing market for preventive vaccines. With its large and diverse population, the region faces significant health challenges, including the burden of infectious diseases such as hepatitis, dengue, and tuberculosis. Increasing healthcare investments, expanding immunization programs, and rising awareness about vaccination are driving the demand for preventive vaccines in this region.
Middle East and Africa (MEA) is characterized by a diverse healthcare landscape, with varying levels of healthcare infrastructure and accessibility across countries. Despite facing challenges such as limited healthcare resources and infrastructure, the region is witnessing efforts to improve vaccination coverage and control the spread of infectious diseases like polio, measles, and hepatitis. Vaccination campaigns supported by international organizations are helping to address these challenges and expand access to preventive vaccines in the region.
Latin America, comprising countries like Brazil, Mexico, and Argentina, is also an emerging market for preventive vaccines. The region has made significant progress in expanding vaccination coverage and reducing the burden of vaccine-preventable diseases through national immunization programs and collaborative initiatives. However, disparities in healthcare access and socioeconomic factors pose challenges to achieving universal vaccine coverage, driving the need for targeted interventions and partnerships to strengthen immunization efforts.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Preventive Vaccines Market. These factors include; Market Drivers, Restraints and Opportunities Analysis,
Drivers, Restraints and Opportunity Analysis
Drivers
- Immunization
- Disease Prevention
- Public Health Initiatives
-
Research and Development - Research and development (R&D) in the Global Preventive Vaccines Market is a driving force behind innovation, aimed at addressing existing and emerging infectious diseases. Pharmaceutical companies, biotech firms, and academic institutions invest significantly in R&D to develop new vaccines, improve existing ones, and explore novel technologies. This includes research into diverse vaccine platforms such as mRNA, viral vectors, and recombinant DNA, offering promising avenues for enhanced efficacy, safety, and scalability. Additionally, R&D efforts focus on vaccine delivery systems, adjuvants, and formulation techniques to optimize immunogenicity and broaden vaccine coverage across different age groups and populations.
Collaborative partnerships play a crucial role in accelerating vaccine development, leveraging collective expertise, resources, and infrastructure. Public-private partnerships between governments, industry stakeholders, and global health organizations facilitate preclinical and clinical research, vaccine manufacturing, and distribution initiatives. Furthermore, initiatives such as the Coalition for Epidemic Preparedness Innovations (CEPI) and the Global Alliance for Vaccines and Immunization (GAVI) foster international collaboration to address global health challenges and ensure equitable access to vaccines. These collaborative efforts streamline R&D processes, mitigate financial risks, and expedite the translation of scientific discoveries into life-saving vaccines.
Emerging infectious diseases and pandemics underscore the urgency of R&D investments in preventive vaccines. Events such as the COVID-19 pandemic highlight the need for rapid vaccine development, manufacturing scale-up, and global distribution networks to curb transmission and mitigate the impact of infectious outbreaks. Consequently, governments, philanthropic organizations, and industry partners allocate substantial funding towards vaccine research, clinical trials, and infrastructure development. These investments not only strengthen pandemic preparedness but also drive innovation in vaccine technologies, paving the way for more agile and responsive public health interventions in the face of evolving infectious threats.
Restraints
- Vaccine Hesitancy
- Supply Chain Challenges
- Regulatory Barriers
-
Affordability and Accessibility - Affordability and accessibility are critical considerations in the Global Preventive Vaccines Market, ensuring equitable distribution and uptake of vaccines across diverse populations worldwide. High vaccine prices can pose significant barriers, particularly in low- and middle-income countries, limiting access to life-saving immunization. Addressing affordability concerns requires collaborative efforts among governments, international organizations, and vaccine manufacturers to develop sustainable pricing models, negotiate bulk purchase agreements, and implement subsidy programs. Additionally, technology transfer initiatives and capacity-building efforts support local vaccine production, driving down costs and enhancing accessibility in resource-limited settings.
Accessibility encompasses not only financial affordability but also geographical availability and logistical feasibility. Remote and marginalized communities often face challenges accessing healthcare services, including vaccination clinics and distribution networks. To improve accessibility, innovative delivery strategies such as mobile vaccination units, community outreach programs, and school-based immunization campaigns are employed to reach underserved populations. Furthermore, investments in healthcare infrastructure, cold chain storage systems, and transportation networks strengthen vaccine distribution channels, ensuring timely and efficient delivery to remote areas and urban centers alike.
Global initiatives such as the COVAX facility and the Vaccine Alliance (GAVI) prioritize affordability and accessibility as core principles in expanding vaccine coverage worldwide. By leveraging economies of scale, pooled procurement mechanisms, and financial support mechanisms, these initiatives negotiate affordable vaccine prices and facilitate equitable distribution to countries in need. Additionally, advocacy efforts and public awareness campaigns raise awareness about the importance of vaccination, promoting uptake and reducing hesitancy among populations. Ultimately, ensuring affordability and accessibility of preventive vaccines is essential for achieving universal health coverage and advancing global health equity.
Opportunities
- Expanded Market Reach
- Technological Advancements
- Public-Private Partnerships
-
Pandemic Preparedness Investments - Pandemic preparedness investments are crucial components of the Global Preventive Vaccines Market, reflecting the need to anticipate and mitigate the impact of infectious disease outbreaks on a global scale. Governments, international organizations, and private sector stakeholders allocate resources towards research, development, and infrastructure to enhance readiness for pandemics. Investments in vaccine development platforms, such as mRNA technology, viral vectors, and recombinant DNA, enable rapid response capabilities, accelerating vaccine production timelines and facilitating the development of vaccines against emerging pathogens.
Furthermore, pandemic preparedness investments focus on strengthening manufacturing capacity and distribution networks to ensure timely and equitable access to vaccines during public health emergencies. Building flexible and scalable vaccine manufacturing facilities, investing in advanced production technologies, and establishing strategic stockpiles of essential vaccine components are critical measures to enhance supply chain resilience and responsiveness. Collaborative initiatives, such as the Advanced Market Commitment (AMC) and public-private partnerships, facilitate early procurement agreements and funding commitments for pandemic vaccine development, incentivizing pharmaceutical companies to prioritize research and development efforts.
Moreover, investments in surveillance, monitoring, and early warning systems bolster global health security by enhancing disease detection and response capabilities. By investing in epidemiological research, genomic sequencing, and data-sharing mechanisms, stakeholders can identify emerging infectious threats, track transmission patterns, and inform public health interventions effectively. Additionally, investments in public health infrastructure, healthcare workforce training, and community engagement initiatives strengthen pandemic preparedness and resilience at the local level, enabling effective containment and mitigation strategies during outbreaks. Overall, pandemic preparedness investments play a pivotal role in safeguarding global health, protecting vulnerable populations, and mitigating the socio-economic impact of infectious disease pandemics.
Competitive Landscape Analysis
Key players in Global Preventive Vaccines Market include;
- AstraZeneca Plc
- Emergent Biosolutions
- GeoVax
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer
- Sanofi S.A.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Region
- Global Preventive Vaccines Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Immunization
- Disease Prevention
- Public Health Initiatives
- Research and Development
- Restraints
- Vaccine Hesitancy
- Supply Chain Challenges
- Regulatory Barriers
- Affordability and Accessibility
- Opportunities
- Expanded Market Reach
- Technological Advancements
- Public-Private Partnerships
- Pandemic Preparedness Investments
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Preventive Vaccines Market, By Vaccine Type, 2020 - 2030 (USD Million)
- Live/Attenuated Vaccines
- Inactivated Vaccines
- Subunit Vaccines
- Toxoid Vaccines
- Conjugate Vaccines
- Recombinant Vector Vaccines
- DNA Vaccines
- Others
- Global Preventive Vaccines Market, By Disease Indication, 2020 - 2030 (USD Million)
- Pneumococcal Vaccines
- Poliovirus
- Hepatitis
- Influenza
- Measles
- Mumps
- Rubella (MMR)
- Varicella
- Human Papilloma Virus
- Others
- Global Preventive Vaccines Market, By Geography, 2020 - 2030 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Preventive Vaccines Market, By Vaccine Type, 2020 - 2030 (USD Million)
- Competitive Landscape
- Company Profiles
- AstraZeneca Plc
- Emergent Biosolutions
- GeoVax
- GlaxoSmithKline Plc
- Inovio Pharmaceuticals
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis AG
- Pfizer
- Sanofi S.A.
- Company Profiles
- Analyst Views
- Future Outlook of the Market